Professor Jan Lundberg
Dr. Jan Lundberg is a former professor of pharmacology at Karolinska Institutet. His research achievements led to the publication of 500 articles in peer-reviewed scientific journals.
Dr. Lundberg has more than 20 years of leadership experience from executive positions in the global pharmaceutical companies AstraZeneca, and Eli Lilly, and has been involved in more than 200 candidate drugs, and 25 approved products across multiple therapeutic areas.
In addition to his considerable Big Pharma experience, Dr. Lundberg serves on the boards of Ardelyx, Metabolon, TB Alliance, Imaging Analysis Group, Anocca and Betagenon. In addition, Dr. Lundberg has been a member of several governmental committees in both the European Union and the United States.